Leukemia Clinical Trials

 

Acute Lymphoblastic Leukemia (ALL)

Newly Diagnosed or Previously Treated

• Hyper-CVAD + Ofatumumab (2010-0708)
• Hyper-CVAD + Vincristine (2008-0598)
• Hyper-CVAD + Inotuzumab Ozogamycin (CMC-544) (2010-0991)
• Hyper-CVAD + Nelarabine (2006-0328)
• Hyper-CVAD + Ofatumumab (2010-0708)
• Augumented BFM + Ofatumumab (2014-0396)

Salvage Programs

• Ruxolitinib or Dasatinib + hyperCVAD (2014-0521)
• Ibrutinib (2013-0459)
• Nelarabine (2009-0717)
• BMS-906024 - Notch inhibitor (2011-0382)
• A-dmDT390-bisFv (UCHT1) Fusion Protein (2008-0077)
• Hyper-CVAD + Inotuzumab Ozogamycin (CMC-544) (2010-0991)
• L-Grb2 Antisense Oligonucleotide (2003-0578)
• Intrathecal Rituximab (2011-0844)
• Hyper-CVAD + Ponatinib +/- Rituximab (2011-0030)
• MEK162 (2013-0116)
• APTO-253 (ALL,AML,MDS) (2014-0528)
• Bosutinib + Inotuzumab Ozogamicin (2014-0435)
• Oral ABL001 (2014-1019)
• LY3039478 + Dexamethasone  (2015-0020)
• JCAR015 (2015-0140)

Minimal Residual Diesease

• Blinatumomab (2014-0844)

Acute Myelogenous Leukemia (AML)

Newly Diagnosed

• Fludarabine, Ara-C, G-CSF and Gemtuzumab Ozogamicin (2007-0147) 
• ATRA and arsenic +/- Gemtuzumab Ozogamicin (2010-0981)
• CIA vs FLAI (2010-0788)
• Cladribine + Ida + Ara-C (2012-0648)
• Vosaroxin + DAC (2013-0099)
• DAC (2012-1017)
• Cladribine + LD Ara-C alternating DAC (2011-0987)
• Four arm SCI-110 (2013-0843)
• ABT-199 +/- AZA or DAC (2014-0490)
• SL-401 (2013-0979)
• EPOCH + Ofatumumab (2014-0123)
• ADI-PEG (2014-0865)
• Ibrutinib +/- Cytarabine (2014-0950)
• CPX-351 (2014-0548)
• Omacetaxine + Decitabine (2013-0812)
• SGI-110 v TC (2014-1051)
• Nivolumab, Idarubicin, and Cytarabine (2014-0907)

FLT3 Mutated Only

• AC220 + 5-AZA or LD Ara-C (2012-1047)
• Sorafenib + 5-AZA (2014-0076)

IDH Mutated only

• AG-221 (2014-0408)
• ABT-199 +/- AZA or DAC (2014-0490)
• AG-881 (2015-0343)

Frontline AML Post-Hypomethylating Therapy for MDS

• Nivolumab + 5-AZA (2014-0861)

Secondary Leukemia

• Ruxolitinib + Decitabine (2014-0344)
• CPX-351 (2014-0548)

Mixed Phenotype Acute Leukemia

• Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids (2013-0073)

Salvage

• AC220 + Salvage Therapy (2014-0058)
• AC220 + 5-AZA or LD Ara-C (2012-1047)
• Cladribine + Ida + Ara-C (2012-0648)
• Trametinib + GSK2141795 (2013-0001)
• DAC + Clofarabine + IDA + Ara-C (2012-1064)
• BL-8040 (2012-1097)
• SL-401 (2013-0979)
• SGN-CD33A (2014-0615)
• DS-3032B (2014-0565)
• AG-120 (2014-0800)
• ADI-PEG (2014-0865)
• KPT-330 (2014-0187)
• Ibrutinib +/- Cytarabine (2014-0950)
• E6201 (2014-0777)
• Nivolumab + 5-AZA (2014-0861)
• Lirilumab + 5-AZA (2014-0862)
• Crenolanib + IA and Crenolanib + 5-Aza (2015-0207)
• AlloSCT Initial Salvage Therapy (2014-0358)
• AMG 330 (2015-0296)

CD56-Positive

• Lorvotuzumab Mertansine (2014-0926)

Supportive Care for AML

• CLT-008 (2014-0858)

Maintenance (Patients in CR)

• SL-401 (2014-0860)
• Lenalidomide maintenance for high risk AML (2014-0116)
• Ixazomib as maintenance in Remission (2014-0379)
• SGN-CD33A (2014-0744)
• Nivolumab (2015-0213)

Observational Studies

Myelodysplastic Syndrome (MDS) (Includes CMML)

Specific Situations

• Hypoplastic MDS and aplastic anemia - Horse ATG (2012-0334)
• MDS/MPN - 
  • Ruxolitinib + AZA (2012-0737)
  • Pacritinib (2013-0224)
• FLT3Positive
  •  AC220 + 5-AZA or LD Ara-C (2012-1047)
  • Sorafenib + 5-AZA (2014-0076)
  • E6201 (2014-0777)
  • Crenolanib + IA and Crenolanib + 5-Aza (2015-0207)

RAS Mutated

• BVD-523 (2014-0391)
• Trametinib + GSK2141795 (2013-0001)
• MEK162 (2013-0116)

IDH 1/2 Mutations

• AG-221 (2014-0408)
• AG-120 (2014-0800)
• CB-839 (2014-0152)
• AG-881 (2015-0343)

Post Hypomethylating Agents:

• MEDI4736 (2013-1041)
• Ruxolitinib (2013-0012)
• Eltrombopag (2013-0225)
• Cladribine + Ida + Ara-C (2012-0648)
• Nivolumab + 5-AZA (2014-0861)
• Lirilumab + 5-AZA (2014-0862)
• Omacetaxine (2013-0870)
• CC-486 (2015-0056)
• Rigosertib v Physician's Choice (2015-0360)

Low Risk/IPSS Int-1

• DAC VS AZA (2014-0112)
• DAC VS AZA (2012-0507)
• Ruxolitinib (MDS) (2013-0012)
• Lenalidomide VS Placebo (2009-0737)
• OPN-305 (2014-0432)
• Nivolumab + Ipilimumab with 5-Aza (2014-0930)
• Pacritinib (2013-0224)

IPSS int-2 or high

• SGI-110 (2013-0901)
• AZA +/- Birinapant (2014-0399)
• Ruxolitinib + AZA (2012-0737)
• Cladaribine + LD Ara-C alt. DAC (2011-0987)
• Vosaroxin + DAC (2013-0099)
• ladribine + Ida + Ara-C (2012-0648)
• Omacetaxine + Decitabine (2013-0812)
• Lorvotuzumab Mertansine (2014-0926)

MDS 20% Blasts

• Four arm SCI-110 (2013-0843)
• DAC (2012-1017)
• CIA vs FLAI (2010-0788)
• Nivolumab, Idarubicin, and Cytarabine (2014-0907)

Chronic Lymphocytic Leukemia (CLL)

CLL Immunotherapy

Untreated - early stage

Untreated - all stages 

• Ofatumumab (2011-0520)
• Identifying Prognostic Factors in Frontline FCR (2008-0431)

Mimimal Residual Disease

Prior Therapy

• PRT062070 (2013-0880)
• Ublituximab + TGR-1202 (2013-0566)
• ACP-196 (2013-0907)
• GDC-0199 + Obinutuzumab (2013-0486)
• Ibrutinib vs Ibrutinib+Rituximab (2013-0703)
• Sapacitabine + Cyclophosphamide + Rituximab (2010-0516)                     
• ROR1R CAR-T (2012-0932) 
• ABT-199 (2014-0405) 
• IPI-145 + Obinutuzumab (2014-0794)
• Nivolumab + Ibrutinib (2014-0931)      
•  Lirilumab + Rituximab (2014-0933)
• Urelumab + Rituximab (2014-0932)

Richter’s Transformation  

• Oral Selinexor (2014-0601)
•  Moxetumomab Pasudotox (2013-0302)                       

Other Studies

• Ruxolitinib (2013-0044)
• PCI-32765 (2013-0299)
• 2CDA + Rituximab (2004-0223)
• Lenalidomide (2013-0371)

Chronic Myelogenous Leukemia (CML)

Chronic phase

• Omacetaxine Mepesuccinate (2014-0229)
• Ponatinib (2015-0212)
• Oral ABL001 (2014-1019)
• Dasatinib + Nivolumab (2015-0068)

Accelerated Phase

• Dasatinib + DAC (2011-0333)
• Omacetaxine Mepesuccinate (2014-0229)
• Nilotinib + MEK-162 (2014-0128)
• Bosutinib + Inotuzumab Ozogamicin (2014-0435)
• Oral ABL001 (2014-1019)

Blastic Phase

• Dasatinib + DAC (2011-0333)
• Cladribine + Ida + Ara-C (2012-0648)
• DS-3032B (2014-0565)
• Nilotinib + MEK-162 (2014-0128)

Imatinib failures with T315l mutations (any stage)

• Oral ABL001 (2014-1019)

Minimal Residual Disease

• Ruxolitinib (2012-0697)

Treatment Discontinuation

Supportive Care

• Eltrombopag (2011-0319)

Other Studies

Roll-over Studies

Myeloproliferative Diseases

• Oral Pacritinib vs Best available therapy (Verstovesk/ K. Schroeder) (2013-1001)
• Ruxolitinib + AZA (2012-0737)
• Sotatercept (ACE-011) (2012-0534)
• NS-018 (CIMF) (2011-0090)
• PRM-151 (2013-0051)
• Momelotinib (2014-0145)
• Momelotinib (2013-0977)
• Brentuximab (2012-0734)
• LCL-161 (2013-0612)
• Ruxolitinib + Pracinostat (2014-0445)
• Momelotinib (2014-0258)
• Nivolumab (2014-0962)
• Lorvotuzumab Mertansine (2014-0926)
• SL-401 (2014-0976)
• AG-881 (2015-0343)

MDS/MPD

• Ruxolitinib + AZA (2012-0737)
• KB004 (2010-0509)

CNL/aCML

• Ruxolitinib in Mutation of CSF3R (2014-0764)

Hemophagocytic Lymphohistiocytosis

• Alemtuzumab + Etoposide & Dexamethasone (2014-0989)